C2C Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

C2C Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,200	Closed	-$976K	–	199
2023 Q3	$976K	Sell	1,200 -225	-16%	-$177K	0.14%	79
2023 Q2	$1.04M	Sell	1,425 -200	-12%	-$154K	0.14%	76
2023 Q1	$1.33M	Buy	+1,625	New	+$1.23M	0.22%	55
2022 Q1	–	Sell	-400	Closed	-$253K	–	228
2021 Q4	$253K	Buy	+400	New	+$246K	0.04%	188

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

C2C Wealth Management's REGN Position: Q4 2023 in Review

C2C Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 1,200 shares — an estimated $976K sold.

C2C Wealth Management first reported a position in REGN in Q4 2021 and held it in 4 quarters. The position peaked at $1.33M in Q1 2023. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

C2C Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
C2C Wealth Management sold 1,200 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $976K.
C2C Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 4 quarters.
C2C Wealth Management's Regeneron Pharmaceuticals position peaked at $1.33M in Q1 2023.
1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on C2C Wealth Management's 13F filing for Q4 2023, filed 13 Feb 2024.